The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance
Open accessAbstract
Summary There are two main mechanisms by which cells become multidrug resistant (MDR): by increasing drug efflux pumps on the cell membrane and by increasing anti-apoptotic pathways. The use of nanotechnology to develop nanodelivery systems has allowed researchers to overcome limitations of antineoplastic drugs by increasing the solubility of the drug and decreasing the toxicity to healthy tissues. By encapsulating drugs into nanoparticles that bypass the efflux pumps, drug efflux is reduced, hence increasing the intracellular concentration of the drug. siRNA has the ability to disrupt cellular pathways by knocking down genes, opening the door to down regulating anti-apoptotic pathways. The use of nanocarriers to deliver siRNA, prevents both renal clearance and RNase degradation by protecting siRNA chains, increasing their half life in blood. It has been suggested that co-delivering drugs and siRNA together in the same delivery system would be more effective in overcoming resistance of cancer cells than co-treatment of cancer cells with delivery systems carrying either siRNA or drugs. In this study we discuss the progress of nanoscale co-delivery systems in overcoming multidrug cancer resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
Polymers for Drug Delivery Systems
Liechty, W. B., Kryscio, D. R., Slaughter, B. V., & Peppas, N. A. (2010) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-073009-100847 · Cited by 1,608
Self-citationLipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products
Pardeike, J., Hommoss, A., & Müller, R. H. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.10.003 · Cited by 1,478
Leslie, E. M., Deeley, R. G., & Cole, S. P. C. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.012 · Cited by 1,406
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
Iversen, T.-G., Skotland, T., & Sandvig, K. (2011) · Nano Today · doi:10.1016/j.nantod.2011.02.003 · Cited by 1,239
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Meng, H., Liong, M., Xia, T., Li, Z., Ji, Z., Zink, J. I., & Nel, A. E. (2010) · ACS Nano · doi:10.1021/nn100690m · Cited by 902
Targeting polo-like kinase 1 for cancer therapy
Strebhardt, K., & Ullrich, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1841 · Cited by 841
RNA-Based Therapeutics: Current Progress and Future Prospects
Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819
Mu, L., & Feng, S. S. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00320-6 · Cited by 725
Functionalisation of nanoparticles for biomedical applications
Thanh, N. T. K., & Green, L. A. W. (2010) · Nano Today · doi:10.1016/j.nantod.2010.05.003 · Cited by 705
Soenen, S. J., Rivera-Gil, P., Montenegro, J.-M., Parak, W. J., De Smedt, S. C., & Braeckmans, K. (2011) · Nano Today · doi:10.1016/j.nantod.2011.08.001 · Cited by 699
Mechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Toxicology and clinical potential of nanoparticles
Yildirimer, L., Thanh, N. T. K., Loizidou, M., & Seifalian, A. M. (2011) · Nano Today · doi:10.1016/j.nantod.2011.10.001 · Cited by 676
Chen, A. M., Zhang, M., Wei, D., Stueber, D., Taratula, O., Minko, T., & He, H. (2009) · Small · doi:10.1002/smll.200900621 · Cited by 671
Bcl-2-regulated apoptosis: mechanism and therapeutic potential
Adams, J. M., & Cory, S. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.05.004 · Cited by 658
Wang, Y., Gao, S., Ye, W.-H., Yoon, H. S., & Yang, Y.-Y. (2006) · Nature Materials · doi:10.1038/nmat1737 · Cited by 658
Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation
Nijhawan, D., Fang, M., Traer, E., Zhong, Q., Gao, W., Du, F., & Wang, X. (2003) · Genes & Development · doi:10.1101/gad.1093903 · Cited by 591
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors
Primeau, A. J., Rendon, A., Hedley, D., Lilge, L., & Tannock, I. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1664 · Cited by 499
Ganta, S., & Amiji, M. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800240j · Cited by 490
Drug Delivery and Transport to Solid Tumors
Jang, S. H., Wientjes, M. G., Lu, D., & Au, J. L.-S. (2003) · Pharmaceutical Research · doi:10.1023/a:1025785505977 · Cited by 483
Zhu, C., Jung, S., Luo, S., Meng, F., Zhu, X., Park, T. G., & Zhong, Z. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.077 · Cited by 440
Xiong, X.-B., & Lavasanifar, A. (2011) · ACS Nano · doi:10.1021/nn2013707 · Cited by 411
Sun, T.-M., Du, J.-Z., Yao, Y.-D., Mao, C.-Q., Dou, S., Huang, S.-Y., Zhang, P.-Z., Leong, K. W., Song, E.-W., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn103349h · Cited by 406
Cyclodextrins as Drug Carrier Molecule: A Review
Rasheed, A. (2008) · Scientia Pharmaceutica · doi:10.3797/scipharm.0808-05 · Cited by 394
Persidis, A. (1999) · Nature Biotechnology · doi:10.1038/5289 · Cited by 372
Singh, A., Boldin-Adamsky, S., Thimmulappa, R. K., Rath, S. K., Ashush, H., Coulter, J., Blackford, A., Goodman, S. N., Bunz, F., Watson, W. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1401 · Cited by 367
Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant Cancer
Saad, M., Garbuzenko, O. B., & Minko, T. (2008) · Nanomedicine · doi:10.2217/17435889.3.6.761 · Cited by 367
siRNA-based approaches in cancer therapy
Devi, G. R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700931 · Cited by 353
The influence of structure on the activity and toxicity of Pt anti-cancer drugs
Hambley, T. W. (1997) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(97)00023-4 · Cited by 348
EGFR-Targeted Magnetic Nanoparticle Heaters Kill Cancer Cells without a Perceptible Temperature Rise
Creixell, M., Bohórquez, A. C., Torres-Lugo, M., & Rinaldi, C. (2011) · ACS Nano · doi:10.1021/nn201822b · Cited by 325
Self-citationPatil, Y. B., Swaminathan, S. K., Sadhukha, T., Ma, L., & Panyam, J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.048 · Cited by 304
Caldorera-Moore, M. E., Liechty, W. B., & Peppas, N. A. (2011) · Accounts of Chemical Research · doi:10.1021/ar2001777 · Cited by 301
Self-citationPreparation and characterization of solid lipid nanoparticles loaded with doxorubicin
Subedi, R. K., Kang, K. W., & Choi, H.-K. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.04.008 · Cited by 301
Targeted nanodelivery of drugs and diagnostics
Phillips, M. A., Gran, M. L., & Peppas, N. A. (2010) · Nano Today · doi:10.1016/j.nantod.2010.03.003 · Cited by 297
Self-citationMembrane Transporters and Channels
Huang, Y., Anderle, P., Bussey, K. J., Barbacioru, C., Shankavaram, U., Dai, Z., Reinhold, W. C., Papp, A., Weinstein, J. N., & Sadée, W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3884 · Cited by 285
Taratula, O., Garbuzenko, O. B., Chen, A. M., & Minko, T. (2011) · Journal of Drug Targeting · doi:10.3109/1061186x.2011.622404 · Cited by 245
Molecular imaging and therapy of cancer with radiolabeled nanoparticles
Hong, H., Zhang, Y., Sun, J., & Cai, W. (2009) · Nano Today · doi:10.1016/j.nantod.2009.07.001 · Cited by 244
Cao, N., Cheng, D., Zou, S., Ai, H., Gao, J., & Shuai, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.061 · Cited by 229
Expert opinion: Responsive polymer nanoparticles in cancer therapy
Liechty, W. B., & Peppas, N. A. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.08.004 · Cited by 226
Self-citationMicro- and nanotechnologies for intelligent and responsive biomaterial-based medical systems
Caldorera-Moore, M., & Peppas, N. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.09.002 · Cited by 217
Self-citationChen, Y., Bathula, S. R., Li, J., & Huang, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.125906 · Cited by 216
Wu, J. H., Lu, Y., Lee, A., Pan, X., Yang, X., Zhao, X. B., & Lee, R. J. (2007) · PubMed · Cited by 216
Lai, C.-J., Bao, R., Tao, X., Wang, J., Atoyan, R., Qu, H., Wang, D.-G., Yin, L., Samson, M., Forrester, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3360 · Cited by 212
Song, X. R., Cai, Z., Zheng, Y., He, G., Cui, F. Y., Gong, D. Q., Hou, S. X., Xiong, S. J., Lei, X. J., & Wei, Y. Q. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.02.018 · Cited by 211
Polymers in Small-Interfering RNA Delivery
Singha, K., Namgung, R., & Kim, W. J. (2011) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0293 · Cited by 198
Nanoparticles Targeted With NGR Motif Deliver c-myc siRNA and Doxorubicin for Anticancer Therapy
Chen, Y., Wu, J. J., & Huang, L. (2010) · Molecular Therapy · doi:10.1038/mt.2009.291 · Cited by 190
Kaneshiro, T. L., & Lu, Z.-R. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.06.026 · Cited by 186
Cheng, D., Cao, N., Chen, J., Yu, X., & Shuai, X. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.057 · Cited by 184
Li, J., Wang, Y., Zhao, M., Tan, C., Li, Y., Le, X., Ji, L., & Mao, Z. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.12.035 · Cited by 182
Kerbel, R. S., Klement, G., Pritchard, K. I., & Kamen, B. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf093 · Cited by 177
Martins, S., Costa-Lima, S., Carneiro, T., Cordeiro-da-Silva, A., Souto, E. B., & Ferreira, D. C. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.032 · Cited by 165
New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin
GARCIAFUENTES, M., TORRES, D., & ALONSO, M. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.12.030 · Cited by 161
Nanoprobes for biomedical imaging in living systems
Koo, H., Huh, M. S., Ryu, J. H., Lee, D., Sun, I., Choi, K., Kim, K., & Kwon, I. C. (2011) · Nano Today · doi:10.1016/j.nantod.2011.02.007 · Cited by 159
Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA
Yu, Y. H., Kim, E. J., Park, D. E., Shim, G., Lee, S. B., Kim, Y. B., Kim, C., & Oh, Y. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.11.002 · Cited by 154
Yadav, S. K., van Vlerken, L. E., Little, S. R., & Amiji, M. M. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0790-y · Cited by 152
Chemosensitization of cancer cells by siRNA using targeted nanogel delivery
Dickerson, E. B., Blackburn, W. H., Smith, M. H., Kapa, L. B., Lyon, L. A., & McDonald, J. F. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-10 · Cited by 151
Cancer chemotherapy: A critical analysis of its 60 years of history
Galmarini, D., Galmarini, C. M., & Galmarini, F. C. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.03.002 · Cited by 151
Multifunctional quantum dots for personalized medicine
Zrazhevskiy, P., & Gao, X. (2009) · Nano Today · doi:10.1016/j.nantod.2009.07.004 · Cited by 151
Functional nanoparticles for molecular imaging guided gene delivery
Liu, G., Swierczewska, M., Lee, S., & Chen, X. S. (2010) · Nano Today · doi:10.1016/j.nantod.2010.10.005 · Cited by 151
Emerging nanomaterials for targeting subcellular organelles
Huang, J. G., Leshuk, T. M. C., & Gu, F. (2011) · Nano Today · doi:10.1016/j.nantod.2011.08.002 · Cited by 150
Supramolecular assemblies in functional siRNA delivery: Where do we stand?
Aliabadi, H. M., Landry, B. K., Sun, C., Tang, T., & Uludağ, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.11.079 · Cited by 147
Kato, T., Natsume, A., Toda, H., Iwamizu, H., Sugita, T., Hachisu, R., Watanabe, R., Yuki, K., Motomura, K., Bankiewicz, K. S., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.88 · Cited by 131
Potential clinical applications of siRNA technique: benefits and limitations
Chen, S., & Zhaori, G. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02400.x · Cited by 107
Shim, G., Han, S.-E., Yu, Y.-H., Lee, S. B., Lee, H. Y., Kim, K., Kwon, I. C., Park, T. G., Kim, Y. B., Choi, Y. S., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.017 · Cited by 103
Beh, C. W., Seow, W. Y., Wang, Y., Zhang, Y., Ong, Z. Y., Ee, P. L. R., & Yang, Y. Y. (2008) · Biomacromolecules · doi:10.1021/bm801109g · Cited by 100
Zhao, X.-Q., Xie, J., Chen, X.-G., Sim, H. M., Zhang, X., Liang, Y.-J., Singh, S., Talele, T. T., Sun, Y.-L., Ambudkar, S. V., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076299 · Cited by 97
Longo-Sorbello, G. S. A., & Bertino, J. R. (2001) · PubMed · Cited by 92
c-Myc overexpression and endocrine resistance in breast cancer
McNeil, C. M., Sergio, C. M., Anderson, L. R., Inman, C. K., Eggleton, S. A., Murphy, N., Millar, E. K. A., Crea, P., Kench, J. G., Alles, M. C., et al. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.09.028 · Cited by 86
Kim, C., Shah, B. P., Subramaniam, P., & Lee, K. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100460h · Cited by 86
(2000) · Nature Biotechnology · doi:10.1038/80051 · Cited by 77
Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA
Chang, R. S., Suh, M. S., Kim, S., Shim, G., Lee, S. B., Han, S., Lee, K. E., Jeon, H., Choi, H.-G., Choi, Y., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.017 · Cited by 67
Knapp, D. C., Mata, J. E., Reddy, M. T., Devi, G. R., & Iversen, P. L. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200301000-00006 · Cited by 67
A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA.
Nakamura, K., Lila, A. A., Matsunaga, M., Doi, Y., Ishida, T., & Kiwada, H. (2011) · Molecular Therapy · doi:10.1038/mt.2011.174 · Cited by 64
Huang, H., Kuo, W., Chou, M., & Huang, Y. (2011) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.33055 · Cited by 61
Kang, S. H., Cho, H. J., Shim, G., Lee, S. B., Kim, S.-H., Choi, H.-G., Kim, C., & Oh, Y. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0569-4 · Cited by 60
Baldwin, R. L., Tran, H., & Karlan, B. Y. (2003) · PubMed · Cited by 60
Combination Drug Delivery Strategy for the Treatment of Multidrug Resistant Ovarian Cancer
Zahedi, P., Souza, R. D., Huynh, L., Piquette‐Miller, M., & Allen, C. J. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100323z · Cited by 58
Ebert, S. P., Wetzel, B. R., Myette, R. L., Conseil, G., Cole, S. P. C., Sawada, G. A., Loo, T. W., Bartlett, M. C., Clarke, D. M., & Detty, M. R. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3004398 · Cited by 47
Wang, Y., Chen, Q., Jin, S., Deng, W., Li, S., Tong, Q., & Chen, Y. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.683042 · Cited by 31
Cited by
Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., Xiao, X., Yang, Y., Sheng, W., Wu, Y., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.02.006 · Cited by 511
Kemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.019 · Cited by 506
Gandhi, N. S., Tekade, R. K., & Chougule, M. B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.001 · Cited by 394
Polymeric nanostructured materials for biomedical applications
Tang, Z., He, C., Tian, H., Ding, J., Hsiao, B. S., Chu, B., & Chen, X. (2016) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2016.05.005 · Cited by 363
Biomedical applications of metallic nanoparticles in cancer: Current status and future perspectives
Khursheed, R., Dua, K., Vishwas, S., Gulati, M., Jha, N. K., Aldhafeeri, G. M., Alanazi, F. G., Goh, B. H., Gupta, G., Paudel, K. R., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112951 · Cited by 286
Metadata
- Authors
- Creixell, M., & Peppas, N. A.
- Venue
- Nano Today
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 7
- Issue
- 4
- Pages
- 367-379
- ISSN
- 1748-0132 (ISSN-L)
- OpenAlex
- W1988816960
- Cited by
- 331
- References
- 88
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.